Global Combination Antibody Therapy Market, By Type (Antibody/Antibody, Antibody-Drug Conjugates, Bispecific Antibodies, Chemotherapy-Monoclonal Antibodies, Others), Indication (Cancer, HIV, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Combination Antibody Therapy Market Analysis and Size
The global combination antibody therapy market is projected to witness significant growth during the forecast period of 2022 to 2029. The global combination antibody therapy market has undergone revolutionary development in the last few years because of the continued focus on development of targeted cancer therapies that cause fewer side effects. So unlike traditional cytotoxic chemotherapies, that interfere with the process of cell division and kill rapidly dividing cells in the body, also killing healthy cells in the process, targeted therapies such as combination antibody are found to be more effective.
Data Bridge Market Research analyses a growth rate in the global combination antibody therapy market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Combination Antibody Therapy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Antibody/Antibody, Antibody-Drug Conjugates, Bispecific Antibodies, Chemotherapy-Monoclonal Antibodies, Others), Indication (Cancer, HIV, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd (Israel), Seagen Inc. (U.S.), CELGENE CORPORATION (U.S.), Genmab A/S (Denmark)
|
|
Market Opportunities
|
|
Market Definition
Monoclonal antibody drugs are treatments that enlist your body's germ-fighting immune system against diseases, including cancer. Targeted cancer therapies fight cancer cells with more precision, attacking only the molecules that are essential for tumor growth and progression, and leading to potentially lesser side effects.
Global Combination Antibody Therapy Market Dynamics
Drivers
- Increase in Cancer Cases
The increase in cancer cases worldwide boosts the global small cell lung cancer (SCLC) therapeutics market in the forecast period. According to the reports of the American Cancer Society Statistics in 2016, majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with a projected global death rate being 30,000 each year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women leading to 1.59 million deaths in 2012. This boost the market growth.
- Development of Diversified Treatments
Treatments such as phage or yeast display, and transgenic mice, for human monoclonal antibodies generation and also employment of advanced genetic engineering technology offer great benefits to the patients. Thus, it boosts the market growth.
Opportunities
- Patent Expiration Encourages New Launches
Patent expiration of several old companies can make better opportunities for the new market players. Adopting combination therapies is a significant factor contributing to the growth of the monoclonal antibodies market. Additionally, increased R&D fundings are an add-on to the market.
- Growing research activities
There has been increased research activities that are creating more opportunities for the market growth. For instance, in 2008, U.S. based company Biogen Inc. announced the successful phase III clinical trials of Rituxan. In combination with chemotherapy, this drug helped improve progression free survival in patients with relapsed chronic Lymphocytic Leukemia. In 2010, the FDA approved Rituxan in combination with chemotherapy drugs such as fladarabinie and cyclophosphamide (FC) for the treatment of the most common type of Adult Leukemia. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the knowledge of the treatment methods for this disease could limit the growth of the global combination antibody therapy market during the forecast period.
- Increasing Cost Of Treatments
The huge expenditure required for the treatment methods hamper the market growth. Many of the treatments involved in this disease demand high cost and thus at times, it gets difficult for many people, particularly the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.
This global combination antibody therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global combination antibody therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Combination Antibody Therapy Market Scope
The global combination antibody therapy market is segmented on the basis of type, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Antibody/Antibody
- Antibody-Drug Conjugates
- Bispecific Antibodies
- Chemotherapy-Monoclonal Antibodies
- Others
Indication
- Cancer
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Blood Cancer
- HIV
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Combination Antibody Therapy Market Regional Analysis/Insights
The global combination antibody therapy market is analyzed and market size insights and trends are provided by type, indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global combination antibody therapy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to increased prevalence of cancer and related disorders and number of generic drugs.
North America dominates the market due to focus of global market players and novel technologies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Combination Antibody Therapy Market Share Analysis
The global combination antibody therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global combination antibody therapy market.
Key players operating in the global combination antibody therapy market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Teva Pharmaceutical Industries Ltd (Israel)
- Seagen Inc. (U.S.)
- CELGENE CORPORATION (U.S.)
- Genmab A/S (Denmark)
SKU-